Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Endovia Health Sciences, Inc. (EDVA)

Endovia says FDA deems CannEpil a minor use for canine bone cancer pain

Neutral Impact 3 of 5 legal/regulatory Written later

Endovia Health Sciences announced that the FDA's Center for Veterinary Medicine determined CannEpil qualifies as a minor use for controlling bone cancer pain in dogs, making it eligible to pursue the conditional approval pathway. The product remains investigational and is not approved or conditionally approved, and the company has not given revenue or financial figures in this filing.

Key points

  • FDA Center for Veterinary Medicine determined CannEpil qualifies as a minor use under the MUMS program
  • Endovia and Lupvindol are scheduled to meet the FDA for a Pre-Submission Conference on November 19, 2026
  • Company is working toward a potential veterinary launch in 2027, subject to FDA approval

The filing

CompanyEndovia Health Sciences, Inc. (EDVA)
Form8-K, current report
Filed with the SECOct 5, 2026, 4:02 PM ET
Accession number0001731122-26-001312

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.